“Specific to China, we saw strong performance in the quarter, and we expect continued strong performance as we go through this year.”

In context

“uestion each to get to as many questioners as possible. Thank you. Operator: [Operator Instructions] Your first question comes from the line of Carter Gould from Barclays. Your line is open. Ed Carter: This is Ed Carter on for Carter. We wanted to ask about GARDASIL. If you could talk about any impact you're seeing in China, either from a demand perspective or disruptions to manufacturing? And in that context, should we think about cadence -- or should we think about cadence over the year being notably different than in the years past? There's just a lot of different crosses play. So any color there would be helpful. Caroline Litchfield: Carter, this is Caroline. Thank you very much for the question. GARDASIL continues to be a great growth driver for our company globally, including China. Specific to China, we saw strong performance in the quarter, and we expect continued strong performance as we go through this year. We have significant demand in China. And as they're off flares, as a result of COVID and potentially lockdown in one part of the country, we have the ability to ensure that we're supplying more of the GARDASIL doses to other parts of the country. So we're, therefore, not anticipating a significant impact to our GARDASIL performance in China as a result of what we're seeing in Shanghai at this moment in time. As it pertains to our supply chain, our company has a very robust supply chain. And we have Plan A and Plan B, if there are any interruptions in the supply chain. So we, again, have no concern for the reliability of our supply chain, but we remain vigilant and focused on the situation at hand. Operator: Thank you. Next up, we have Mohit Bansal from Wells Fargo. Your line is open. Mohi”